Methodological Indication Splits for Comparability in the Relevant Competitive Environment

Methodological indication splits are the ideal solution to make products comparable that compete with each other but have different approved indications on the market.

Because prescription data do not contain indication information, we assign each patient the most likely diagnosis based on assumptions that we define together with you in an iterative process. These assumptions may include, among others, specific pre-, post- and co-medications, certain active ingredient strengths and/or formulations, or physician specialty groups involved at different stages of treatment.

Key benefits of an indication split include:

• Narrowing the competitive environment to truly comparable, indication-relevant substances
• Enabling strategic decisions based on the specific patient populations that matter to you
• Sharpening the target population for more efficient marketing activities and targeting approaches
• Answering medical questions
• Supporting the determination of lines of therapy and regulatory approval processes

Indication splits are a foundational step for more advanced analyses and can be applied to nearly our entire product portfolio. Contact us – we will be happy to advise you.